NASDAQ:TARS Tarsus Pharmaceuticals (TARS) Stock Price, News & Analysis $59.85 +2.16 (+3.74%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$59.92 +0.07 (+0.13%) As of 07/17/2026 05:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tarsus Pharmaceuticals Stock (NASDAQ:TARS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tarsus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$57.38▼$59.9550-Day Range$56.11▼$70.5552-Week Range$38.51▼$85.25Volume971,198 shsAverage Volume1.40 million shsMarket Capitalization$2.57 billionP/E RatioN/ADividend YieldN/APrice Target$90.67Consensus RatingModerate Buy Company Overview Tarsus Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life. In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders. The company leverages a multidisciplinary pipeline strategy, combining small‐molecule drug discovery with novel delivery approaches to optimize tissue penetration and minimize systemic exposure. Tarsus collaborates with clinical research sites across North America and Europe to execute its global development plans and intends to explore strategic partnerships for later‐stage commercialization and distribution. Founded in 2018 and headquartered in Westlake Village, California, Tarsus Pharmaceuticals was established by a team of industry veterans with deep experience in ophthalmology, neurology and pharmaceutical development. The company’s leadership team includes seasoned executives with track records in launching ophthalmic products and navigating regulatory pathways. Tarsus maintains corporate offices in the United States and engages with regulatory authorities to advance its portfolio toward potential approval and market launch.AI Generated. May Contain Errors. Read More Tarsus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreTARS MarketRank™: Tarsus Pharmaceuticals scored higher than 55% of companies evaluated by MarketBeat, and ranked 468th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingTarsus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 2 strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialTarsus Pharmaceuticals has a consensus price target of $90.67, representing about 51.5% upside from its current price of $59.85.Amount of Analyst CoverageTarsus Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Tarsus Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tarsus Pharmaceuticals are expected to grow in the coming year, from ($0.86) to $2.87 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tarsus Pharmaceuticals is -52.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tarsus Pharmaceuticals is -52.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTarsus Pharmaceuticals has a P/B Ratio of 7.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tarsus Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.15% of the float of Tarsus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTarsus Pharmaceuticals has a short interest ratio ("days to cover") of 6.24.Change versus previous monthShort interest in Tarsus Pharmaceuticals has recently increased by 18.28%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTarsus Pharmaceuticals does not currently pay a dividend.Dividend GrowthTarsus Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.25 News SentimentTarsus Pharmaceuticals has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Tarsus Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest5 people have searched for TARS on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Tarsus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tarsus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,452,821.00 in company stock.Percentage Held by Insiders9.64% of the stock of Tarsus Pharmaceuticals is held by insiders.Percentage Held by Institutions90.01% of the stock of Tarsus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tarsus Pharmaceuticals' insider trading history. Receive TARS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TARS Stock News HeadlinesGuggenheim Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)July 16 at 6:47 PM | theglobeandmail.comTarsus Pharmaceuticals (TARS) Replaces Its Commercial Chief While iRenix Talks ContinueJuly 15 at 11:14 PM | finance.yahoo.comPrint this before your next tradeBill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It's a single-page, seven-point filter designed to help traders identify weak setups before placing any options trade. Print it, keep it at your desk, and run it before every trade. The download link expires soon.July 18 at 1:00 AM | Profits Run (Ad)Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH) and Tarsus Pharmaceuticals (TARS)July 15 at 8:13 AM | theglobeandmail.comTarsus Pharmaceuticals Announces Chief Commercial Officer TransitionJuly 13, 2026 | tipranks.comTarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of GrowthJuly 13, 2026 | globenewswire.comTarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells 10,000 Shares of StockJune 23, 2026 | insidertrades.comTarsus Pharmaceuticals (NASDAQ:TARS) Director Sells $183,384.32 in StockJune 18, 2026 | insidertrades.comSee More Headlines TARS Stock Analysis - Frequently Asked Questions How have TARS shares performed this year? Tarsus Pharmaceuticals' stock was trading at $81.88 at the beginning of 2026. Since then, TARS stock has decreased by 26.9% and is now trading at $59.85. How were Tarsus Pharmaceuticals' earnings last quarter? Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) released its earnings results on Wednesday, May, 6th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.24. The business had revenue of $162.05 million for the quarter, compared to the consensus estimate of $149.60 million. Tarsus Pharmaceuticals had a negative net margin of 9.02% and a negative trailing twelve-month return on equity of 14.19%. Read the conference call transcript. When did Tarsus Pharmaceuticals IPO? Tarsus Pharmaceuticals (TARS) raised $88 million in an initial public offering on Friday, October 16th 2020. The company issued 5,500,000 shares at $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James acted as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers. Who are Tarsus Pharmaceuticals' major shareholders? Top institutional investors of Tarsus Pharmaceuticals include Assenagon Asset Management S.A. (2.20%), Wasatch Advisors LP (0.86%), E. Ohman J or Asset Management AB (0.11%) and Wedge Capital Management L L P NC (0.06%). Insiders that own company stock include Bobak R Azamian, William J Phd Link, Seshadri Neervannan, Bryan Wahl, Jeffrey S Farrow, Aziz Mottiwala, Dianne C Whitfield, Elizabeth Yeu Lin, Andrew D Goldberg, Jose M Trevejo and Katherine Goodrich. View institutional ownership trends. How do I buy shares of Tarsus Pharmaceuticals? Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tarsus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tarsus Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings5/06/2026Today7/18/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 For the last 8 days, TARS's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TARS CIK1819790 Webwww.tarsusrx.com Phone949-409-9820FaxN/AEmployees50Year Founded2017Price Target and Rating Average Price Target for Tarsus Pharmaceuticals$90.67 High Price Target$100.00 Low Price Target$68.00 Potential Upside/Downside+51.5%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$66.42 million Net Margins-9.02% Pretax Margin-8.20% Return on Equity-14.19% Return on Assets-8.89% Debt Debt-to-Equity Ratio0.21 Current Ratio3.74 Quick Ratio3.71 Sales & Book Value Annual Sales$451.36 million Price / Sales5.70 Cash FlowN/A Price / Cash FlowN/A Book Value$8.09 per share Price / Book7.40Miscellaneous Outstanding Shares43,020,000Free Float38,876,000Market Cap$2.57 billion OptionableOptionable Beta0.50 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:TARS) was last updated on 7/18/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredCentral banks bought 710 tonnes - this fund pays monthlyGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredElon’s message for AmericaElon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...Stansberry Research | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredThe only metrics you should watch as a day trader.Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...The TradingPub | SponsoredEx-CIA Insider: “Prepare for a Mid-Term Meltdown”Former CIA and Pentagon advisor Jim Rickards - who correctly called the 2008 recession, Trump's 2016 election,...Paradigm Press | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TARS Stock Alerts